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Abstract
With the increasing publicity of marijuana due to recent legislation, it is pertinent that the effects of fetal exposure
to the drug are assessed. While in utero cannabis exposure has been associated with early pregnancy failure, birth
defects and developmental delay, the mechanisms of such outcomes are largely unexplained. Furthermore, the use
of cannabinoids in cancer treatment via growth inhibition and apoptosis may indicate how cannabis exposure likely
harms a growing fetus. Cannabinoid signaling is required for proper pre-implantation development, embryo
transport to the uterus, and uterine receptivity during implantation. In post-implantation development, cannabinoid
signaling functions in a multitude of pathways, including, but not limited to, folic acid, VEGF, PCNA, MAPK/ERK, and
BDNF. Disrupting the normal activity of these pathways can significantly alter many vital in utero processes,
including angiogenesis, cellular replication, tissue differentiation, and neural cognitive development. This paper aims
to demonstrate the effects of cannabis exposure on a developing embryo in order to provide a molecular
explanation for the adverse outcomes associated with cannabis use during pregnancy.
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Background
It has long been established that smoking tobacco dur-
ing pregnancy causes increased risk of miscarriage, in-
creased placental problems, reduction of birth weight,
and a variety of birth defects [1]. In light of the recent
legalization of marijuana in Colorado, Washington,
Alaska and Washington, D.C., we felt it important to
establish and publicize the causative relationship
between cannabis usage and embryological outcomes.
The main psychoactive cannabinoid in marijuana is
delta-9-tetrahydrocannabinol (THC), which has a half-
life of approximately 8 days in fat deposits and can be
detected in blood for up to 30 days before becoming en-
tirely eliminated from the blood [2]. These characteris-
tics act as a direct risk factor to the developing embryo,
as the maternal tissues act as reservoirs for THC and
other cannabinoids.
Certain drugs cross the placenta to reach the embryo
in the same manner as oxygen and other nutrients [3].
Drugs consumed during pregnancy can act directly on
the embryo, or they can alter placental function, which
is critical for normal growth and development. Ingestion
of drugs can interfere with these functions, resulting in
compromised fetal development and growth [3]. THC
readily crosses the placenta, which, in conjunction with
slow fetal clearance, results in prolonged fetal exposure
to THC, even after consumption is discontinued [2].
The use of marijuana in early pregnancy is associated
with many of the same risks as tobacco, including miscar-
riage, congenital malformations, and learning disabilities
[4]. Adverse effects of marijuana use during pregnancy
have been exacerbated over the years, as THC levels in
marijuana have increased nearly 25-fold since 1970 [5].
This paper looks to examine recent studies on cannabi-
noids and embryonic development in order to establish
the mechanisms through which these cannabinoids act. A
full overview of these mechanisms and downstream
effects are provided in Fig. 1 and Table 1.
Methods
To compile the literature analyzed in this review,
MEDLINE was searched for English language articles be-
tween 1975 and 2015. First, exploratory searches were
conducted using the key words cannabinoid AND
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embryo AND development. Searches were then con-
ducted using combinations of the Medical Subject Head-
ing (MeSH) terms Cannabinoids, Cannabis, Marijuana,
and Fetal Development. We reviewed the identified arti-
cles for applicability and selected the articles that
included the in vitro or in vivo effects of altered canna-
binoid signaling, in vivo concentrations of cannabis fol-
lowing cannabinoid use or infusion, and epidemiological
effects of cannabis use. Additional articles were selected
from the bibliographies of searched articles.
Metabolism, physiologic concentration, and placental
transfer
The pharmacokinetics of cannabis has been shown to
vary depending on the route of administration, which
can impact the rate of drug absorption [6]. Smoking is a
preferred method of consumption for many cannabis
users because of its rapid drug delivery and its rapid
manifestation in physiological effects [7]. When smok-
ing, drug exposure varies with the number and duration
of puffs, as well as the hold time, inhalation volume, or
smoking topography [8–10]. Studies have been con-
ducted with various dosages of marijuana cigarettes to
determine the concentrations of THC and its metabo-
lites both immediately after smoking and several days
afterwards.
In a study by Huestis et al., a computer-paced smoking
procedure was implemented to control the number of
puffs, length of inhalation, and time between puffs in
several human subjects. A low dosage marijuana
cigarette was defined as having 16 mg THC (1.75 %),
while a high-dosage cigarette was defined as having
Fig. 1 Overview of cannabinoid action on fetal developmental mechanisms. A flowchart of the proposed mechanisms by which cannabis affects
embryological and fetal development. Note that many “end result” outcomes were observed in animal models
Friedrich et al. BMC Pharmacology and Toxicology  (2016) 17:45 Page 2 of 13
34 mg THC (3.55 %) [11]. Immediately after inhalation
of the marijuana cigarette, THC concentrations in blood
were measured via a continuous blood-withdrawal
pump, which collected blood at a rate of 5 ml/min.
Mean THC concentrations were 7.0 ± 8.1 ng/mL and
18.1 ± 12.0 ng/mL upon single inhalation of low and
high dose marijuana cigarettes, respectively [11]. The
THC concentrations increased rapidly and reached
peaks of 84.4 ng/mL and 162.2 ng/mL for low and high
dosage marijuana cigarettes, respectively, at 9 min in
both cases [12]. A similar study found that smoking two
marijuana cigarettes with approximately 25 mg THC per
cigarette (2.57 %) elevated plasma concentrations of
THC by approximately 300 ng/mL [7].
Huestis et al define a high dosage of THC as 34 mg,
however, this underestimates the potency cannabis that
is sold and used today. In 2010, researchers working
with the National Institute on Drug Abuse analyzed
46,211 samples of cannabis confiscated by domestic law
enforcement between 1993 to 2008 [13]. The data reveal
a steady increase in average concentrations of THC, in-
creasing from 3.4 % (34 mg per cigarette) in 1994 to
8.8 % (84 mg per cigarette) in 2008 [13]. The mean con-
centration of THC in hashish, a popular preparation of
cannabis, was found to range to be from 12.69 to
15.56 % during the same period [13].
Ingestion of cannabinoids by the oral route is another
common method, especially for therapeutic applications.
Ingestion of cannabinoids results in slower absorption
with lower, more-delayed peak THC concentrations
[6, 14]. A study by Ohlsson et al measured THC con-
centrations based on GC/MS experiments, and found
that the peak THC concentrations ranged from 4.4 to
11 ng/mL, which occurred 1–5 h following ingestion
of 20 mg of THC in a chocolate cookie [6]. The
lower peak of oral ingestion of THC versus smoking
can be attributed to several factors, including variable
absorption, breakdown of the drug in the stomach, as
well as first–pass metabolism to active 11–OH-THC
and inactive metabolites in the liver [11].
However, Ohlsson et al underestimated the amount of
THC in products available to consumers, as the advent
of legalization has given rise to a niche market of canna-
bis products with artificially elevated concentrations of
Table 1 A summary table of cannabinoid effects on various cellular processes
Specific Protein
or Process
Effect of Cannabinoid on
Protein or Process
Downstream Effect Study Method Study
Angiogenic
proteins
Administration of the cannabinoid
JWH altered the expression of 10
genes which are all directly or




In vivo. Mice bearing s.c.
gliomas injected with JWH
Blazquez et al., 2004. [36]
Apoptosis
(Epithelial tumor)
Treatment of PDV.C57 cells with the
cannabinoid WIN induces apoptosis
Premature cellular death In vitro. Treatment of skin
tumor cells with WIN





Premature cellular death In vitro. HUVEC cells treated
with WIN
Blazquez et al., 2003. [42]
Cellular Migration Cannabidiol treatments causes a





In vivo and In vitro.
Cannabidiol treatment of
HUVEC cells and treatment
of C57/BL6 mice
Solinas et al., 2012. [41]
Ceremides The ceramide-dependent cannabinoid-
induced inhibition of VEGFR-2




In vitro. Mice bearing s.c.
gliomas injected with JWH
and WIN
Blazquez et al., 2004. [36]
Folic acid Chronic Cannabidiol consumption
results in a decrease in folic acid
uptake, while acute Cannabidiol
consumption results in no effect




In vitro. Cannabidiol treatment
of BeWo cells incubated with
folic acid
Araújo et al., 2009. [35]
PCNA Treatment of LNCaP cells with the
cannabinoid WIN results in a
significant decrease in protein




In vitro. LNCaP cancer cells
treated with WIN
Sarfaraz et al., 2005. [40]
VEGF Cannabidiol significantly inhibits




In vitro. Inhibition of the in-vitro
angiogenesis in HUVEC Cells
Solinas et al., 2012. [41]
Abbreviations: HUVEC Human umbilical vein endothelial cell, JWH JWH-133 (Cannabinoid and CB2 agonist), LNCaP androgen-sensitive human prostate
adenocarcinoma cells, PCNA Proliferating cell nuclear antigen, S.c. Subcutaneous, VEGF Vascular endothelial growth factor, WIN WIN-55,212-2 (Cannabinoid and CB1 agonist)
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cannabinoids [15, 16]. Today, legally available edible
preparations of cannabis, for example, baked goods or
chocolate bars sold in San Francisco, California, are found
to contain THC content ranging from 1 mg of THC to
greater than 1200 mg of THC per item when analyzed via
high-performance liquid chromatography [17].
Once cannabinoids are present in the bloodstream,
their lipophilic nature allows them to readily cross the
placenta and enter the fetal bloodstream [18, 19]. Studies
conducted on pregnant dogs demonstrate that THC is
deposited in fetal fat at concentrations that are approxi-
mately 30 % of maternal plasma levels [20]. A study in-
vestigating placental transfer of THC in Rhesus
monkey’s found that THC was detectable in fetal plasma
15 min after infusion of the mother. Furthermore, fetal
plasma levels of THC equilibrated to maternal levels
within 3 h [19]. In this same study, mothers infused with
0.3 mg/kg of THC generated a peak THC concentration
of 1419 ng/ml [19]. In contrast, a 70 kg woman consum-
ing a cannabis chocolate bar containing 180 mg of THC
would equate to THC consumption of 2.6 mg/kg.
The studies to be presented in this paper detail the ef-
fects of cannabinoids delivered at concentrations as low as
100 ng/ml. As discussed above, the potency of modern
day cannabis product allows for maternal and fetal con-
centration of cannabinoids to easily exceed this threshold.
Pre-implantation
THC is a component of the cannabinoid family, working
mainly through the G protein-coupled receptors cannabin-
oid receptor type 1 (CB1) and type 2 (CB2) [21]. The
activation of these receptors occurs via exogenous cannabi-
noids (i.e. THC) as well as endogenous cannabinoids (i.e.
anandamide). Therefore, manipulation of endogenous can-
nabinoids can be used as a model for studying the effects of
increased exogenous cannabinoid exposure. Both CB1 and
CB2 are found in the female reproductive system and work
in an inhibitory fashion by decreasing the activity of adeny-
lyl cyclase and protein kinase A (Fig. 2). In terms of the
effects of cannabinoid signaling on pre-implantation events,
CB1 is of greater importance, as it is found in the oviduct,
uterus, and from the late two-cell stage through the blasto-
cyst stage of the embryo [1, 21, 22].
While translation of cannabinoid signaling studies in
mice to humans have not yet been performed, evidence
suggests that cannabinoid signaling plays an important role
in the development of the mouse embryo. For example, in
mouse models of CB1-/-, CB2-/-, and CB1-/- x CB2-/-
double mutants, where there is no cannabinoid signaling,
mutant embryos were recovered from the oviduct 3 and
4 days post fertilization showing asynchronous develop-
ment relative to wild type [23]. Conversely, increased can-
nabinoid signaling is associated with developmental arrest
of two-cell embryos in vitro in a dose-dependent manner
[21]. Increased cannabinoid signaling via CB1 agonists has
also been shown to lead to decreased blastocyst viability
and a reduced number of trophectoderm cells, a decreased
rate of zona-hatching, and inhibition of implantation [24].
Strong evidence supports the belief that these changes are
associated with the CB1 mediated modulation of calcium
channel activity, inhibition of adenylyl cyclase, activation of
phospholipase C, and stimulation of mitogen-activated
protein kinases (MAPKs) which include extracellular sig-
nal-regulated kinases (ERK), c-Jun N-terminal kinases
(JNK), and p38 [1, 25–28]. In sum, deviations from homeo-
static cannabinoid signaling highlight the importance of
tightly regulated cannabinoid signaling for proper pre-
implantation development.
In addition to the changes associated with increased
cannabinoid signaling, there are changes in gene expres-
sion. In order to assess these changes, mice without fatty
acid amide hydrolase (FAAH) were used. FAAH is in-
volved with the degradation of anandamide, an endogen-
ous cannabinoid, and therefore acts as a model for
increased cannabinoid signaling. FAAH is also involved
in regulating the magnitude and duration of anandamide
signaling [29]. The FAAH-/- mice showed differential ex-
pression in genes related to cell migration most signifi-
cantly, suggesting that cell migration in mice is defective
with increased cannabinoid signaling [29, 30]. These
findings support the changes associated with abnormalities
that occur through the cell signaling pathways and CB1.
Along with proper embryological development, implant-
ation is also dependent on timely transport of embryos
from the oviduct to the uterus, as dysfunctional transport
can increase the risk of ectopic pregnancy in women [31].
Figure 3a illustrates fertilization occurring in the ampulla
followed by the subsequent divisions of the embryo in the
oviduct as it travels towards the uterus. It is important to
note that as the concentration of cannabinoids increases,
there is an increase in muscle relaxation in the uterine
lumen, as shown in Fig. 3c. However, as the cannabinoid
concentration increases, there is also an associated loss of
constriction that is essential for proper movement of the
ovulated egg to the uterus for implantation [27, 31]. This
observation is speculated to be facilitated by the presence
of β-2 adrenergic and α-1 adrenergic receptors that cause
sphincter relaxation and contraction, respectively [31].
CB1 expression in the muscularis of the oviduct is associ-
ated with the α-1 and β-2 receptors, leading to the specu-
lation that cannabinoid signaling is functionally coupled
to signaling through the adrenergic receptors, therefore
facilitating oviductal motility [1, 31]. These notions are
further supported as FAAH-/- mice, as well as wild-type
mice with elevated exogenous cannabinoid ligands,
observed impaired oviductal-uterine transport, which is
defined as greater oviduct embryo retention [27, 31]. Con-
sistent with current mouse data, venous blood obtained
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from women with ectopic pregnancies has been found
to have significantly elevated cannabinoid levels when
compared to normal pregnant controls, indicating that
the link between altered cannabinoid signaling and im-
paired transport of the embryo most likely exists in
humans [32]. This study found that mean anandamide
levels (+/- SD) in the ectopic pregnancy group were
0.78 +/−0.04 nM, and healthy controls had anandamide
concentrations of 0.63 +/−0.04 nM [32]. In comparison,
smoking two marijuana cigarettes has been demon-
strated to elevate plasma concentrations of THC by
approximately 300 ng/mL [7].
While THC affects embryological development and
transportation to the uterus, issues still arise from the
process of implantation, illustrating the wide variety of
ways in which increased cannabinoid signaling can alter
implantation. In the mouse uterus specifically, the win-
dow of time for implantation is very limited such that it
is receptive on day 4 post-fertilization, while it is consid-
ered non-receptive on day 5 [2, 24]. Implantation can be
divided into the pre-receptive, receptive and refractory
stages. The levels of endogenous cannabinoids are bi-
phasic during this process as there are increased levels
during the pre-receptive and refractory but low during
Fig. 2 CB1 cannabinoid receptor signaling and regulation of neural stem/progenitor cell proliferation. CB1 receptors are coupled to Gi proteins,
thereby mediating the inhibition of adenylyl cyclase (AC) and protein kinase A (PKA). CB1 receptor coupling to Gi signalling is also associated with
activation of the extracellular signal-regulated kinase (ERK) pathway via different mechanisms. Direct activation of the PI3K/Akt and ERK pathways by
CB1 receptors may converge, thus synergizing with their activation by other receptors such as growth factor receptors with tyrosine kinase activity
(RTK). CB1 receptor-induced activation of RTKs can occur by promoting the processing of membrane-bound growth factor inactive precursors to yield
active growth factors, or by activating intracellular Src family protein kinases. In some circumstances, CB1 activity can antagonize RTK-mediated ERK
signaling. Activation of the CB1 receptor ultimately controls different transcriptional regulators, including CREB, STAT-3, PAX-6 and β-catenin. The CB1
receptor may also regulate mammalian target of rapamycin complex 1 (mTORC1) in NPs as it occurs in differentiated neurons. Permission to use figure
was obtained from [44] and Creative Commons (https://creativecommons.org/licenses/by/4.0/)
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the receptive [1, 27, 33]. Implantation fails when blasto-
cysts are exposed to increased levels of cannabinoid sig-
naling, ultimately blocking calcium channels and ERK
activity [33]. Aside from the biphasic level of cannabin-
oid signaling during the implantation stage, this notion
is supported as levels of cannabinoids at implantation sites
are lower than inter-implantation sites with higher FAAH
expression to promote the implanting process [2, 27, 33].
In sum, increased levels of CB1 activation through canna-
binoid signaling during the receptive stage of implantation
is associated with decreased uterine receptivity and
reinforces the importance of tight regulation of this signal-
ing pathway.
Folic acid
Folic acid, also known as Vitamin B9, is essential for nu-
merous bodily functions, including normal development
and growth of the placenta and embryo [34]. It cannot
be synthesized de novo, and thus must come from the
diet or supplementation [34]. Folates are incredibly im-
portant within cells, as they function in one-carbon
transfer reactions in growth and repair reactions, includ-
ing the de novo biosynthesis of purine and pyrimidine
precursors of nucleic acids, metabolism of amino acids
and initiation of protein synthesis in mitochondria [35].
Folic acid is therefore vital to the process of DNA repli-
cation in dividing cells. Folic acid deficiency is associated
with low birth weight, increased risk of spontaneous
abortion, as well as neural tube defects such as spina
bifida or anencephaly [35]. The process whereby folic
acid travels from mother to embryo is critical to under-
standing the pathway through which THC and other
cannabinoids may interfere with folic acid. Maternal to
fetal folic acid uptake occurs transcellularly at polarized,
Fig. 3 a A cartoon of oviductal transport of preimplantation embryos in mice. Ovulated eggs are fertilized in the ampulla of the oviduct. Fertilized
eggs through successive cell divisions form morulae. Morulae pass through the utero-tubal junction to enter into the uterine lumen. b A schematic
diagram of a cross-section of the oviduct. Ep, epithelium. c A proposed scheme of contraction–relaxation waves of oviductal muscularis at the
utero-tubal region influenced by varying concentrations of AEA. In the absence of AEA, increased release of norepinephrine (NE) produces muscular
contractions, resulting in narrowing of the lumen. At higher concentrations of AEA, endocannabinoid signaling through CB1 reduces the release of NE,
thus relaxing the muscularis, widening the lumen. Thus, appropriate endocannabinoid signaling creates waves of contraction–relaxation, moving
forward embryos from the oviduct into the uterine lumens [27]. With permission from Elsevier Inc
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epithelial-like syncytiotrophoblasts; this is the pathway
that cannabinoids can disrupt [35].
Araújo et al. looked at the effects of cannabinoids on
BeWo cells, which are a human choriocarcinoma cell line
that can uptake folic acid, making them an appropriate
placental synctiotrophoblast model [35]. This research
showed that at physiological pH (7.5), the primary recep-
tors involved in folic acid apical uptake are folate receptor
α (FRα) and reduced folate transporter 1 (RFC1) [35]. FRα
is a glycosylphosphatidylinositol-anchored protein, and is
found on the apical side of the syncytiotrophoblasts [35].
FRα exhibits high affinity binding with folic acid, and is
capable of internalizing it through receptor-mediated
endocytosis [35]. On the other hand, RFC1 is a facilitative
carrier that is driven by the transmembrane H+ gradient.
Overall, RFC1 has a much greater affinity for reduced fo-
lates over non-reduced folates [34]. The proton-coupled
folate transporter (PCFT) is another transporter that uses
a high-affinity proton-coupled mechanism to translocate
folates across the cellular membrane, acting optimally at
acidic pH [35].
Araújo et al’s results ultimately demonstrated that acute
cannabinoid consumption resulted in no effect on the ap-
ical uptake of folic acid, while the chronic (48 h) effect of
THC manifested itself in a significant decrease in folic
acid uptake [35]. Figure 5a and b shows the effect of acute
cannabinoid consumption on folic acid uptake. These cells
were incubated at 37 °C for 6 min with folic acid in the ab-
sence or presence of THC or anandamide. The results
show that at physiological pH of 7.5, anandamide caused a
15 ± 4 % decrease in uptake, while THC had no effect on
uptake [35]. Figure 4 also shows the effects of chronic can-
nabinoid consumption on folic acid uptake. At physio-
logical pH of 7.5, 100 nmol/L of THC is shown to cause a
significant folic acid uptake decrease of 20 ± 4 %. These
data ultimately demonstrate that in BeWo cell lines,
chronic consumption of THC results in a markedly de-
creased folic acid uptake. This suggests that marijuana use
during pregnancy could result in folic acid deficiencies
and possibly developmental defects.
Cellular growth factors
Cannabinoid exposure poses an acute risk to the devel-
oping human embryo through its ability to interfere with
crucial modulators of cellular growth and angiogenesis
such as Vascular Endothelial Growth Factor (VEGF), by
its ability to restrict movement of Human Umbilical
Vein Endothelial Cells (HUVEC), and by its ability to in-
duce apoptosis across multiple cell lineages.
VEGF is considered the most important proangiogenic
molecule due to its expression in a wide variety of human
tissues, and because of potency and ability to regulate per-
haps every step of the angiogenic cascade [36–39]. Nu-
merous investigations have illustrated that cannabinoid
exposure reduces VEGF expression across multiple cell
lineages in both a dose-dependent and time-dependent
manner [40, 41]. For example, injection of the CB2 agonist
JWH-133 (JWH), a non-psychoactive cannabinoid, in
mice bearing subcutaneous gliomas resulted in a reduc-
tion of the expression of 10 genes that are either directly
or indirectly related to the VEGF pathway [36]. The same
experiment also showed that cannabinoid injection re-
sulted in a 50 % reduction in expression of VEGF-A and
an 80 % reduction in expression of VEGF-B [36]. Add-
itionally, Solinas et al. demonstrate that exposing HUVEC
cells to Cannabidiol (CBD), a peripherally active cannabin-
oid, significantly inhibited the VEGF induced outgrowth
of capillary-like structures (Fig. 5.) [41]. It is proposed that
the mechanism of this action is via a ceramide-dependent
cannabinoid-induced inhibition of the VEGF receptor 2
(VEGFR-2) action [36].
Cannabinoid administration to cell lines also disrupts
cellular functions such as DNA replication and cellular
motility in vivo and in vitro. Treatment of androgen-
sensitive human prostate adenocarcinoma cells (LNCaP)
with WIN-55,212-2 (WIN), the cannabinoid and CB1
agonist, results in a significant decrease in the expres-
sion of Proliferating Cell Nuclear Antigen (PCNA), an
essential processivity factor for DNA replication [40].
With respect to cellular motility, it is found that admin-
istration of cannabinoids to HUVEC in vitro results in a
statistically significant decrease in cellular migration, al-
though no appreciable apoptosis was observed [41].
Given that cellular migration and replication are crucial
processes to a developing embryo and proliferating fetal
tissues, cannabinoid exposures during the fetal develop-
ment process may result in adverse outcomes.
In vivo and in vitro exposure to cannabinoids induces
apoptosis across numerous cell lineages. Blazquez et al.
find that HUVEC death occurs when cultured cells are
treated with WIN [42]. Similarly to WIN’s effect in um-
bilical stem cells, in vivo cannabinoid-induced apoptosis
has been replicated in both the PDV.C57 epithelial
tumor cell line and in treatment of LNCaP cells [40, 43].
The cellular environment of a growing tumor closely
models that of a developing embryo– an environment of
rapidly proliferating and differentiating tissues seeking
vascular access for growth. While apoptosis of tumor
cells is the desired effect of cancer treatment, embryo-
logical growth requires viable cells and vascular prolifer-
ation. In sum, the ability of cannabinoids to induce
apoptosis in both tumor cells lines and HUVEC lines
may translate to an analogous and undesired apoptotic
effect in a developing embryo.
MAPK/ERK and neural development
The regulation of neuronal cell differentiation and
growth occurs through various signaling pathways in the
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embryo and is critical to proper fetal brain development.
Type I cannabinoid receptors are expressed abundantly
in the fetal brain, suggesting they play a vital role in the
development of the embryologic neural system [44].
Neural stem cells (NSCs), the precursor cells in develop-
ment, can differentiate into either neurons or glial cells,
such as astrocytes or oligodendrocytes, by the process of
neurogenesis during embryo development [45]. Research
suggests that CB1 receptor activity by cannabinoids has
an important regulatory role in determining the fate of
neural cells, through processes such as cell cycle pro-
gression and proliferation, specification, axonal migra-
tion and morphogenesis [44]. While current research
suggests varying, and at times, contradictory effects of
cannabinoids on neural development and highlights the
need for more advanced studies, the importance of such
research is to show that exogenous cannabinoids can
disrupt the underlying homeostasis required for proper
development to occur.
The role of the CB1 receptor in neuronal progenitor
cell differentiation was investigated using NSCs obtained
from the cerebral cortexes of mouse embryos and treat-
ment with endocannabinoids, including anandamide and
arachidonyl-2’-chloroethylamide (ACEA) [45]. The re-
sults of this study indicated that when exposed to anan-
damide or ACEA, NSC differentiation into neurons is
promoted, in comparison to the control. This finding is
indicated by increased cell expression of β-III tubulin, a
neuronal marker, over GFAP, an astrocyte marker, as
well as decreased expression of Nestin, a neuronal
Fig. 4 Acute effect of various cannabinoids upon the apical uptake of 3H-FA by BeWo cells (a, b). The cell monolayers were incubated at 37 °C for 6 min
with 3H-FA (50 nmol/l) at pH 7.5 (a) or pH 6.5 (b) in the absence or presence of the compounds. The tested compounds were THC (n= 9) and anandamide
(Anan; n= 9). 3H-FA uptake in control cells amounted to 0.73 ± 0.08 pmol/mg prot. (n= 18) (a) and 0.81 ± 0.07 pmol/mg prot. (n= 18) (b). The results are
shown as arithmetic means ± SEM. *p< 0.05 compared to control condition. Chronic (48 h) effect of various cannabinoids upon the apical uptake of 3H-FA
by BeWo cells (c, d). The cell monolayers were incubated at 37 °C for 6 min with 3H-FA (50 nmol/l) at pH 7.5 (A) or pH 6.5 (b) in the absence or presence of
the compounds. The tested compounds were THC (n= 9) and anandamide (Anan; n= 9). 3H-FA uptake in control cells amounted to 0.44 ± 0.03 pmol/mg
prot. (n= 15) (a) and 0.62 ± 0.09 pmol/mg prot. (n= 12) (b). The results are shown as arithmetic means ± SEM. *p< 0.05 compared to control condition.
[Adapted from 35]. With Permission from Karger Inc. via RightsLink
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precursor marker indicating the undifferentiated state. In
addition, ACEA-treated NSCs showed a higher degree of
maturation and complexity after differentiation, illustrated
by increased neuronal length, number of neurites, and
branching [45]. Studying the expression of genes involved
in the differentiation pathways suggested that activation of
the CB1 receptor by endocannabinoids increased expres-
sion of genes promoting neuronal cell fate and decreased
those genes that promote further NSC proliferation in
vivo [45]. Therefore, the role of endocannabinoids in alter-
ing rate, commitment and morphology of NSC differenti-
ation could be detrimental to this tightly regulated and
sensitive process of neural development.
Interestingly, similar evidence regarding neuronal differen-
tiation has also been observed with the chronic treatment of
adult rat hippocampal NSCs with HU210, a synthetic can-
nabinoid, and anandamide [46]. A significant increase in
newborn neurons was observed in the hippocampal dentate
gyrus, a location that is capable of producing a large increase
in neurons from its existing NSC population in adults [47].
While this observation may prove useful in the future treat-
ment of neurological disorders, such unregulated neuron
proliferation deviates from embryological homeostasis.
The Mitogen-activated protein kinase (MAPK) signal-
ing pathway has been studied in the endocannabinoid
dysregulation of NSC differentiation. The MAPK family
is highly conserved in the control of numerous cellular
processes, such as proliferation, differentiation and the
stress response [28]. Three specific subfamilies of MAPK
have been studied in relation to cannabinoids- p38-
MAPK, c-Jun N-terminal kinases (JNK) and extracellular
signal-regulated kinase (ERK), with the most extensive
research focusing on ERK.
The p38-MAPK and JNK subfamilies are involved in the
cellular stress response, which is important in the develop-
ing embryo. Rat and mouse hippocampal slices exposed to
both endogenous (anandamide) and exogenous (THC)
cannabinoids exhibited an increase in p38-MAPK phos-
phorylation, but no effect on JNK [28]. The activation of
p38-MAPK was discovered to involve CB1 receptors, but
the mechanism is still unknown; this activation of
p38-MAPK was observed in adult hippocampal slices. Since
both exogenous and endogenous cannabinoids can cross
the blood-placental barrier, this raises the concern that this
may be observed in the embryo. This is significant because
p38-MAPK activity acts as a switch for the commitment of
embryonic stem (ES) cells to neurogenesis (p38 not
expressed) and cardiomyogenesis (p38 expressed) early in
embryo development, and also acts differentially through-
out the developmental stages [48]. Thus disregulation of
Fig. 5 Cannabidiol inhibits in vitro endothelial morphogenesis and angiogenesis. a HUVECs were incubated on a Matrigel substrate in the presence of M199
alone (Control –) or of M199 supplemented with 2 % FBS (Control +), in the absence or presence of different concentrations of CBD for 6 h at 37 °C. CBD
interfered with HUVEC organization in capillary-like networks. b HUVEC spheroids, were embedded in collagen gel supplemented with VEGF (30 ng ·mL-1) in
the absence (Control) or in the presence of CBD (1 mM). Representative photos of each experimental group are shown. c Quantification of the sprouting.
The results are expressed as the mean ± SEM of the cumulative sprout length of the capillary-like structures emerging from 24 to 26 individual spheroids per
experimental group. **p< 0.01 compared to spheroids from control HUVECs, Dunnett’s t-test [Adapted from 41]. With permission from Wiley and Sons Inc.
via RightsLink
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the p38-MAPK signaling pathways can be detrimental to
ES cell commitment and differentiation.
Experiments in vitro using rat and mice hippocampal
slices and in vivo in mice were performed to investigate
the exposure of cannabinoid agonists on ERK regulation
[49]. The hippocampus is vital in learning and memory,
making it possible that in utero disruptions to its forma-
tion via cannabinoid exposure could manifest post-natally.
The results showed a significant increase in ERK1 and
ERK2 activation by phosphorylation in the hippocampus
when exposed to cannabinoids, including both ananda-
mide and THC (Fig. 6). When the CB1 receptor gene was
knocked out, ERK activation was not observed, helping to
confirm that agonists acted on the receptor [49].
As extensive research on THC’s effects on the embryo is
lacking, cannabinoids have also been reported to inhibit
the ERK pathway within the hippocampus [50]. Using cor-
tical neuron progenitors taken from 17-day-old rat em-
bryos previously exposed to chronic administration of
anandamide for 2 weeks, decreased neuronal differenti-
ation was observed. The CB1 receptor activity of endocan-
nabinoids was determined to inhibit ERK activation in the
dentate gyrus of the rat hippocampus (Fig. 7) [50]. These
results are seemingly contradictory to evidence that
Fig. 6 Cannabinoid agonists stimulate ERK phosphorylation in rat hippocampal slices. a Rat hippocampal slices were incubated at 35 °C, as described
in Materials and Methods, for 50 min before the addition of vehicle (Control), 1 μM anandamide, 1 μM 2-AG, 1 μM CP 55940, 100 μM WIN 55212–2,
0.2 μM LPA, or 0.1 μM Δ9-THC for 5 min, in the absence or in the presence of 100 μM SR 141716A applied 30 min before. Slices were homogenized in
SDS; 60 μg of protein per sample were subjected to immunoblot analysis using antibodies specific for the dually phosphorylated (active) forms of
ERK1 and ERK2 (Blot P-ERK). After stripping, the membranes were reprobed with anti-ERK (Blot ERK) antibodies. b For quantification the optical densities
of P-ERK2-immunoreactive bands were measured, normalized to the optical densities of total ERK2 in the same samples, and expressed as percentages
of controls. Data correspond to means ± SEM. Statistical analysis was done with ANOVA (F (13,24) = 22.8; p < 0.0001) followed by t test (treated vs control:
***p < 0.001, **p < 0.01; treated in the presence of SR141716A vs in its absence: °° p < 0.01, ° p < 0.05). c, d Quantification of the effects of 2-AG on ERK2
active form: time course (drug concentration 1 μM) (c); concentration–response curve (treatment for 5 min) (d). Immunoreactivity was quantified by
scanning densitometry using NIH image 1.62 software. Values are means ± SEM of four to eight independent experiments and are expressed as
percentages of the maximal increase above unstimulated control values [49]. With open permission from the Journal of Neuroscience
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showed cannabinoids activated the ERK pathway in
mice hippocampus both in vitro and in vivo [49].
However, this varying evidence may be due in part to
different experimental conditions and cannabinoid ex-
posure amounts. This highlights the sensitivity of the
neural development processes to the effects of com-
pounds appearing in concentrations varying from
their homeostatic concentrations.
Similarly, the reported inhibition of NSC differenti-
ation due to the reduction of the ERK pathway appears
contradictory to evidence showing an increase in neural
differentiation upon cannabinoid-induced reduction of
the ERK pathway [45, 50]. These contradictory results
may be in part explained by the differing roles of the
ERK pathway in various parts of the neural system de-
velopment, as the studies analyzed hippocampi and cere-
bral cortices respectively. This evidence significantly
shows that neural development is tightly regulated and
varies greatly in different locations, and therefore canna-
binoid exposure disruption of the signaling processes
critical to this development could be detrimental and
must be further studied.
The MAPK/ERK pathway regulates the gene expres-
sion through the activation of transcription factors and
thus indicates many ways development could be altered
[51]. ERK pathway regulation has been implicated in
neural processes, such as synaptic plasticity, learning
and memory, as well as general processes, such as gene
transcription, translation and cytoskeletal rearrangement
[49, 52]. While it is still unclear what role exactly canna-
binoids play in NSC differentiation and the ERK pathway
in different parts of the neural system, any alteration
from normal homeostatic pathway levels at such a crit-
ical time and location in development is significant
nonetheless and should be a target of future research
[49, 50]. Furthermore, MAPK signaling is involved in
the broader RAS-MAPK pathway downstream of recep-
tor tyrosine kinase signaling, which is involved in cell
fate decisions of developmental processes such as neural
patterning and limb development [52].
Fig. 7 Anandamide inhibits neuronal differentiation via CB1. E17 cortical neuron progenitor differentiation was performed in the presence of the
indicated agents. a Immunofluorescence with anti-β-tubulin III antibody after 24 h of 5 μM AEA incubation in the absence or presence of 2 μM
SR141716. b Percentage of neurons bearing neurites longer than twice (left panel) or five times (right panel) the cell body after quantification of
immunofluorescence photographies. c Western blot of β-tubulin III and vimentin expression during the indicated days of cortical neuron
development in the absence or presence of AEA. Loading controls were carried out with an anti-α-tubulin antibody. d Western blot of
β-tubulin III (left panel) and Neu N (right panel) in cortical neuron extracts from cultures in the absence or presence of AEA and prevention
of the AEA effect by SR141716. Results correspond to four different experiments. Significantly different from controls *p < 0.01 [50]. With
Permission from the Journal of Biochemistry
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THC also induces brain-derived neurotrophic factor
(BDNF) mRNA transcription through the ERK signaling
pathway [51]. BDNF is a growth factor that behaves as an
immediate-early gene involved in synaptic efficiency, neur-
onal survival and new neuron differentiation, as well as in
long-term memory. While decreased BDNF is associated
with certain pathologies, including depression, increased
expression has been correlated to in utero valproic acid
(VPA) exposure [53]. VPA is an antiepileptic and mood-
stabilizing drug, and its stimulation of BDNF expression
when introduced in utero is associated with increased risk
of congenital malformations and impaired cognition, in-
cluding autism and low IQ. By studying fetal mice brains
exposed to VPA, it has been suggested that the embryonic
brain, which normally contains low BDNF levels, is highly
sensitive to both increases and decreases in the protein,
and that disrupting this tight regulation can alter prenatal
cortical development by altering NSC proliferation and
differentiation [53]. Therefore, future research should look
to assess whether the THC-induced increase in BDNF ex-
pression mimics the post-natal outcomes of the VPA-
induced BDNF stimulation.
The MAPK/ERK pathway also plays a role in the for-
mation of the blood-placental barrier [51]. Using mouse
embryos and placentae, it was determined that normal
MAPK/ERK signaling is required to form the syncytio-
trophoblast that make up the blood-placental barrier.
The barrier allows for separation of fetal and maternal
circulation within the placenta and is vital for embryo
development. Therefore, deviations from the normal sig-
naling pathway represents another means by which can-
nabinoids could potentially alter development, although
this has yet to be reported on in the literature.
In embryogenesis, ERK signaling between tissues may
be important in the ultimate 3D organization. In mouse
embryos, dephosphorylated forms of ERK1/2 were used to
map out domains of signaling activation during embryo-
genesis [52]. Activated ERK domains were found at all
stages of embryo development, with variations in pattern
complexity and activation time. For example, while CNS
domains showed more sustained ERK activation, many
processes such as blood vessel formation, neural crest mi-
gration, somite remodeling and PNS development showed
dynamic pulses [52]. This indicates that spatial and tem-
poral patterns of ERK activation are highly regulated with
regards to timing, location, intensity and duration to en-
sure proper shaping of the embryo, and thus disrupting
this precise signaling may alter these processes.
Conclusions
Under normal physiologic conditions, cannabinoid sig-
naling exhibits a wide-range of downstream effects em-
bryologically, as is illustrated by Fig. 1. This breadth of
action ultimately manifests in the symptoms associated
with cannabis use during pregnancy, including miscar-
riage, congenital malformations, and learning disabilities
[1]. Cannabinoids have received renewed attention in
the field of cancer treatment due to their pharmacologic
activities in vivo as cell growth inhibitors, restrictors of
cellular motility, and their ability to induce apoptosis
across multiple cell lineages [40, 41]. However, by the
same mechanisms that cannabinoids show promise in
the field of cancer treatment, they prove equally danger-
ous to the viability and health of a developing embryo. A
summary of these mechanisms is provided in Table 1.
The effects of cannabinoids on pre-implantation and
embryologic development have the potential to elicit
harmful outcomes post-natally. While the method of
consumption can affect the severity of the embryologic
effects, it is important to note that this paper is an over-
view of the effects solely of elevated cannabinoid signal-
ing. A common means of cannabis consumption is
smoking, which can add a number of toxins and thereby
amplify harmful effects to the embryo. Given the trend
of marijuana decriminalization and legalization across
the United States, further epidemiological research
should focus on the association between maternal can-
nabinoid use and observation post-natal outcome.
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